Altay raises $37M Series A for oral FSHD drug
What's the deal? Altay TherapeuticsDealroom has a profile for this one. Try Dealroom → has raised $37 million in a Series A financing to advance DX5057, an oral treatment for facioscapulohumeral muscular dystrophy (FSHD). Sound BioventuresDealroom has a profile for this one. Try Dealroom → and HealthCapDealroom has a profile for this one. Try Dealroom → co-led the round.
New investors Fountain Healthcare PartnersDealroom has a profile for this one. Try Dealroom →, Biogen New Ventures, Pappas CapitalDealroom has a profile for this one. Try Dealroom →, and Global BioAccess FundDealroom has a profile for this one. Try Dealroom → also joined.
What's the endgame? DX5057 is an oral small molecule designed to inhibit DUX4, a transcription factor whose aberrant expression in skeletal muscle drives FSHD. The proceeds will fund Phase 1 and Phase 2 proof-of-concept trials, with a Phase 1 safety study expected to begin in the first quarter of 2027.
Why now? No disease-modifying therapies are currently approved for FSHD. "There are no disease-modifying therapies approved for FSHD, and the patient community is in need of a durable, practical solution," said chief executive officer James Breitmeyer.
Altay says DX5057 acts systemically to shut down DUX4 at its source, distributing to affected muscle to inhibit the target deeply.
Who's backing it? Investors pointed to the company's preclinical work as a draw. "Altay has done the difficult lead discovery and preclinical work and has delivered an oral small molecule candidate on its way into clinical development," said Ester Sklarsky of Sound Bioventures.
The round builds on earlier support. Since 2022, non-profit SOLVE FSHDDealroom has a profile for this one. Try Dealroom → has invested nearly $7 million in seed financing alongside board-level leadership. Four new directors from Sound Bioventures, HealthCap, Fountain Healthcare Partners, and Biogen New Ventures will join Altay's board.
The signal: At $37 million, this Series A sits in the upper tier of financings by size. The backing — including a corporate venture arm in Biogen New Ventures — signals investor appetite for small-molecule approaches to rare muscular diseases that still lack approved therapies.
Read more: markets.financialcontent.com
Image credit: Altay Therapeutics
